| 77.29 1.26 (1.66%) | 07-31 16:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 92.77 | 1-year : | 108.36 |
| Resists | First : | 79.43 | Second : | 92.77 |
| Pivot price | 75.74 |
|||
| Supports | First : | 74.2 | Second : | 70.97 |
| MAs | MA(5) : | 77.14 |
MA(20) : | 75.55 |
| MA(100) : | 92.98  |
MA(250) : | 116.57 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 64.3 |
D(3) : | 69.2 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 157.45 | Low : | 70.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZTS ] has closed below upper band by 20.3%. Bollinger Bands are 66.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 77.62 - 77.93 | 77.93 - 78.2 |
| Low: | 74.07 - 74.44 | 74.44 - 74.77 |
| Close: | 76.63 - 77.25 | 77.25 - 77.79 |
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Sun, 02 Aug 2026
Glenmede Trust Co. NA Boosts Stock Holdings in Zoetis Inc. $ZTS - MarketBeat
Sun, 02 Aug 2026
Bank of America Corp DE Has $571.15 Million Stock Position in Zoetis Inc. $ZTS - MarketBeat
Sat, 01 Aug 2026
Summitry LLC Invests $21.25 Million in Zoetis Inc. $ZTS - MarketBeat
Fri, 31 Jul 2026
Janus Henderson Group PLC Trims Stake in Zoetis Inc. $ZTS - MarketBeat
Fri, 31 Jul 2026
Kentucky Retirement Systems Has $4.88 Million Stock Holdings in Zoetis Inc. $ZTS - MarketBeat
Thu, 30 Jul 2026
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 418 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 18,790 (K) |
| Shares Short P.Month | 16,110 (K) |
| EPS | 6.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 28 % |
| Operating Margin | 36.5 % |
| Return on Assets (ttm) | 15.5 % |
| Return on Equity (ttm) | 67.7 % |
| Qtrly Rev. Growth | 2.9 % |
| Gross Profit (p.s.) | 16.33 |
| Sales Per Share | 22.73 |
| EBITDA (p.s.) | 9.7 |
| Qtrly Earnings Growth | 6 % |
| Operating Cash Flow | 2,790 (M) |
| Levered Free Cash Flow | 1,780 (M) |
| PE Ratio | 12.67 |
| PEG Ratio | 1.7 |
| Price to Book value | 0 |
| Price to Sales | 3.4 |
| Price to Cash Flow | 0 |
| Dividend | 0.52 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|